New cocktail aims to outsmart resistant colorectal cancer
NCT ID NCT05627635
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a combination of chemotherapy (FOLFOX), an anti-angiogenic drug (bevacizumab), and two immunotherapies (botensilimab and balstilimab) in 20 patients with MSS metastatic colorectal cancer, a type that usually doesn't respond to immunotherapy. The goal is to see if this four-drug approach is safe and can shrink tumors or slow disease progression. The study is currently active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FOLFOX chemotherapy, bevacizumab, botensilimab, and balstilimab
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with MSS metastatic colorectal cancer, a type that typically does not respond to immunotherapy alone.
- What could go wrong
- This is an early-phase trial with only 20 participants, so results may not apply broadly. The combination of multiple drugs also increases the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLON ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- Can a cholesterol drug help immunotherapy fight colorectal cancer?
- Adding a Blood-Vessel blocker to maintenance chemo may extend control of advanced colorectal cancer